Project description
Harnessing statistical analyses to improve multiple myeloma outcomes
Multiple myeloma is a type of bone marrow cancer affecting white blood cells called plasma cells. These cells help the body fight infections by making antibodies that recognise and attack invaders. In multiple myeloma, cancer cells that produce abnormal proteins accumulate in the bone marrow, destroying bone and displacing healthy blood cells. The cancer can affect multiple areas of the body, including the spine, skull, pelvis and ribs, hence the term 'multiple myeloma'. The relapse rate is 100 % – it is not curable but can go into remission. However, treatments are available. The EU-funded LIMORD project is developing a statistical tool that will be incorporated into a software package for clinical use, enabling more accurate patient classification, earlier relapse detection and better prognosis estimation. The tool will support personalised medicine and improve patient outcomes.
Fields of science
- natural sciencescomputer and information sciencessoftware
- natural sciencescomputer and information sciencesartificial intelligencemachine learningreinforcement learning
- medical and health scienceshealth sciencespersonalized medicine
- natural sciencesmathematicsapplied mathematicsstatistics and probability
Programme(s)
Funding Scheme
MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)Coordinator
75794 Paris
France
See on map
Partners (1)
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
0200 Canberra
See on map